alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › glp-1-analogue

glp-1-analogue

4 studies tagged glp-1-analogue, dated 2017-03-15 to 2020-07-19. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Correction to: Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study) 2020-07-19
  2. The investigation of protective effects of glucagon-like peptide-1 (GLP-1) analogue exenatide against glucose and fructose-induced neurotoxicity 2019-05-01
  3. Post-treatment with the GLP-1 analogue liraglutide alleviate chronic inflammation and mitochondrial stress induced by Status epilepticus 2018-03-09

Studies

4 studies carry this tag.

Date range

2017 to 2020

Top journals

  • Behavioural brain research 1
  • Epilepsy research 1
  • The International journal of neuroscience 1
  • Trials 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Correction to: Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study)

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Trials 2020-07-19 Drug development

    An amendment to this paper has been published and can be accessed via the original article.

  2. The investigation of protective effects of glucagon-like peptide-1 (GLP-1) analogue exenatide against glucose and fructose-induced neurotoxicity

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. The International journal of neuroscience 2019-05-01 Drug development

    Diabetes mellitus (DM) is one of the most common metabolic disorders characterized by hyperglycemia due to insufficiency of insulin and/or insulin resistance.

  3. Post-treatment with the GLP-1 analogue liraglutide alleviate chronic inflammation and mitochondrial stress induced by Status epilepticus

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Epilepsy research 2018-03-09 Drug development

    Glucagon-like peptide-1(GLP-1) is a growth factor that has neuroprotective and anti-inflammatory properties.

  4. GLP-1 analogue CJC-1131 prevents amyloid β protein-induced impirments of spatial memory and synaptic plasticity in rats

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Behavioural brain research 2017-03-15 Drug development

    Although amyloid β protein (Aβ) has been recognized as one of the main pathological characteristics in the brain of Alzheimer's disease (AD), the effective strategies against Aβ neurotoxicity are still deficient up to now.

All topic tags with their study counts